RNS - Another Application7 Nov 2019 07:07
Extract only read full RNS
Angle PLC Cancer centre shows Parsortix use in melanoma
Source: RNS Non-Regulatory
TIDMAGL
Angle PLC
07 November 2019
For immediate release 7 November 2019
ANGLE plc ("the Company")
LEADING CANCER CENTRE DEMONSTRATES USE OF PARSORTIX IN MELANOMA
Parsortix harvests cancer cells from blood for analysis where cell surface markers systems are limited
CTCs predicted relapse earlier than standard of care imaging
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that leading European cancer centre, University Medical Centre Hamburg-Eppendorf (UKE), Germany has published results of work demonstrating that ANGLE's Parsortix(R) system can be used as a liquid biopsy to investigate prediction and monitoring of therapy responses for melanoma patients.